Biomedical

Colorado State University is constructing the $34.6 million Johnson Family Equine Hospital on the South Campus in Fort Collins. Located in the Veterinary Health Complex on CSU’s South Campus, the 85,000-sf project will provide translational research and treatment facilities including sophisticated operating rooms, an equine sports medicine center, advanced imaging suites, a dedicated isolation unit, and rehabilitation and therapy areas.

SiO2 Materials Science is investing $163 million to expand its production capacity for vaccine vials and syringes in Auburn, Ala. The company will increase the footprint of its existing facility in the Auburn Technology Park West to create a 70,000-sf manufacturing center with additional space for precision injection molding operations. A second molding plant will also be constructed nearby. 

University Hospital Hamburg-Eppendorf is planning to build a 193,000-sf translational medicine hub in Hamburg, Germany. Housing the Campus Research II facility and the Hamburg Center for Translational Immunology, the interdisciplinary complex will provide 150 labs for the study of inflammation, infection, and immunology. The structure will also accommodate collaborative workspaces, instrumentation suites, research offices, and interaction zones.

AstraZeneca is planning to expand its Hurdsfield campus with the construction of a 95,000-sf pharmaceutical manufacturing facility. Accommodating 72 new employees, Building 52 will occupy a remediated brownfield site in Macclesfield in the United Kingdom. The two-story structure will provide leading-edge formulation suites and production lines for the manufacture of prescription medicines.

The Centers for Disease Control and Prevention (CDC) will begin construction in early 2021 on the 160,000-sf High Containment Continuity Laboratory in Atlanta. Designed by a joint venture of Flad Architects and Page, the BSL-4 facility will support the CDC's mission to rapidly detect and mitigate public health hazards. Accommodating approximately 80 investigators, the state-of-the-art laboratory will be one of three centers in the world designed and certified to facilitate diagnostic research on specific, select viruses.

The University of Hawaii at Manoa completed construction in June of 2020 on the $65 million Life Sciences Building in Honolulu. Accommodating the College of Natural Sciences' School of Life Sciences, the 70,000-sf interdisciplinary facility offers six teaching labs, 15 research labs, 28 faculty offices, 52 graduate student workstations, five conference rooms, and a 600-sf student collaboration area.

Trammell Crow Company will break ground in July of 2020 on Fulton Labs in Chicago. Providing wet and dry research environments, the 16-story, 423,454-sf life science facility will offer column-free and long-span layouts as well as a dedicated innovation floor for early-stage companies. Designed for maximum flexibility and scalability, the 16-story structure will integrate advanced mechanical infrastructure to support advanced R&D enterprises, with all labs meeting VC-A vibration criteria to ensure reproducible research results.

Sanofi Pasteur is planning to create the Evolutive Vaccine Facility (EVF) in Neuville sur Saône, France. Representing an investment of €490 million over a five-year period, the structure will house a central unit containing several fully digital production modules, enabling the manufacture of four vaccines simultaneously. This modularity will make it possible to prioritize the delivery of a specific vaccine to address crucial public health issues. The company will also invest €120 million to construct a new R&D center in Marcy-l'Etoile.

AZIsotopes is building a $45 million headquarters and production facility in Bunker Hill, Ind. The project includes the renovation of a 55,000-sf shell building and the construction of a 28,000-sf addtion, which will house a cyclotron vault with walls ten feet thick to isolate the instrument's two 70-ton magnets. Strategically located near Grissom Air Force Base to meet security requirements, the facility will support the creation of medical isotopes for diagnostic testing and clinical treatment. Operations at the site are expected to begin by early 2021.

Access to quick, reliable, and repeated testing has been one of the greatest challenges for businesses, institutions, and individuals during the SARS-CoV-2 crisis. HOK has partnered with Germfree Laboratories to design a mobile testing lab that will help large organizations to meet this urgent need. These self-contained biocontainment facilities can provide advanced, onsite capabilities for any setting.

The South Australian Health and Medical Research Institute will begin construction in July of 2020 on the SAHMRI 2 building in Adelaide. Designed by Woods Bagot, the AUD$500 million project will accelerate the delivery of leading-edge clinical care as well as accommodating growing research programs in health analytics, artificial intelligence, and machine learning. Standing 12 stories above grade with three underground levels, the facility will house the Australian Bragg Centre for Proton Therapy & Research and the SAiGEN Cancer Institute.

Amid sobering reports of job losses in commercial real estate, coupled with months-long construction shutdowns in major markets like Boston and New York, the life sciences sector is poised to experience a less dramatic disruption, and possibly emerge from the pandemic even stronger than it was before. “COVID is a healthcare crisis, so it needs a healthcare solution, and that life sciences and biophparma solution has to be constructed,” says Kevin Chronley, vice president of A/Z Corp. and immediate past president of the Boston Area Chapter of International Society for Pharmaceutical Engineering (ISPE). Chronley predicts that construction will run the gamut from medical device manufacturing and biopharma laboratories to education and training facilities.

Ryvu Therapeutics completed construction in June of 2020 on the R&D Center for Innovative Drugs in Krakow, Poland. Accommodating approximately 300 employees, the $20 million headquarters and research facility will enable the clinical-stage biopharmaceutical company to accelerate the development of novel small molecule therapies that address emerging targets in oncology.

Genomic Partnership Wales is planning to construct a research facility in Cardiff in the United Kingdom to accelerate the development of pharmaceutical therapies. Created by a consortium of government, academic, and medical partners, the project involves the redevelopment of an existing two-story building to provide leading-edge genetics labs, seminar rooms, treatment suites, offices, freezer rooms, and support. The facility will include CL2 biocontainment research suites to ensure compliance with the UK's HBN 15 regulations for pathology services.

Catalent is rapidly scaling up its manufacturing capacity in Bloomington to enable production of a SARS-CoV-2 vaccine candidate that is currently being by developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. The collaboration involves joint investment from Catalent and Janssen to enable large-scale commercial manufacturing by January of 2021, with segregated cGMP production lines operating 24/7 to create approximately a billion doses.